Tempest Therapeutics, Inc. (TPST)
NASDAQ: TPST · Real-Time Price · USD
1.690
-0.030 (-1.74%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Tempest Therapeutics Employees
Tempest Therapeutics had 4 employees as of December 31, 2025. The number of employees decreased by 20 or -83.33% compared to the previous year.
Employees
4
Change (1Y)
-20
Growth (1Y)
-83.33%
Revenue / Employee
n/a
Profits / Employee
-$6,565,500
Market Cap
24.24M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Longeveron | 38 |
| Curis | 24 |
| ABVC BioPharma | 19 |
| NeuroSense Therapeutics | 17 |
| Lantern Pharma | 16 |
| Barinthus Biotherapeutics | 14 |
| Serina Therapeutics | 13 |
| AEON Biopharma | 8 |
TPST News
- 6 days ago - Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T - GlobeNewsWire
- 14 days ago - Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts - GlobeNewsWire
- 4 weeks ago - Tempest Reports Year End 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 5 weeks ago - Tempest Therapeutics Announces Up To $6 Million Private Placement - GlobeNewsWire
- 6 weeks ago - Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026 - GlobeNewsWire
- 2 months ago - Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 - GlobeNewsWire
- 2 months ago - Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets - GlobeNewsWire
- 2 months ago - Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets - GlobeNewsWire